Atlas Trials

Study to Evaluate the Safety and Efficacy of Everolimus, in Subjects With PIK3CA Amplification, PTEN Loss and PIK3CA Mutation Refractory Solid Tumors

Clinical trial NCT02449538 · COMPLETED

Trial details

NCT number
NCT02449538
Sponsor
Samsung Medical Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Solid Tumor
Start date
2015-02-01
Primary completion
2016-04-01
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.